rivoglitazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3055168 |
| CHEMBL ID | 2104753 |
| SCHEMBL ID | 143498 |
| MeSH ID | M0511951 |
| Synonym |
|---|
| rivoglitazone |
| D05739 |
| rivoglitazone (usan/inn) |
| 185428-18-6 |
| r-106056 |
| de-101 |
| cs-011 |
| 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| (+-)-5-(p-((6-methoxy-1-methyl-2-benzimidazolyl)methoxy)benzyl)-2,4-thiazolidinedione |
| unii-3a3n0634q6 |
| rivoglitazone [usan:inn] |
| r 106056 |
| 3a3n0634q6 , |
| 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)- |
| CHEMBL2104753 |
| rivoglitazone [inn] |
| 5-(4-(6-methoxy-1-methyl-1h-benzimidazol-2-ylmethoxy)benzyl)thiazolidin-2,4-dione |
| (+/-)-5-(p-((6-methoxy-1-methyl-2-benzimidazolyl)methoxy)benzyl)-2,4-thiazolidinedione |
| rivoglitazone [who-dd] |
| rivoglitazone [usan] |
| SCHEMBL143498 |
| 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione |
| 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidin-2,4-dione |
| 5-[4-(6-methoxy-1-methyl-1h-benzimidazol-2-ylmethoxy)benzyl]thiazolidin-2,4-dione |
| XMSXOLDPMGMWTH-UHFFFAOYSA-N |
| 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione |
| 5-[4-(6-methoxy-1-methyl-1h-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione |
| DB09200 |
| 7va , |
| (5s)-5-({4-[(6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione |
| bdbm50450235 |
| ( inverted exclamation marka)-5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione |
| BCP06166 |
| Q7338968 |
| HY-106181 |
| DTXSID00870164 |
| CS-0025124 |
Rivoglitazone is an efficacious, safe and well-tolerated TZD which improved glycaemic control in Chinese type 2 diabetic patients up to 3 months.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rivoglitazone is a potent thiazolidinedione agent with demonstrated glycemic benefits over a 6-month period in subjects with type 2 diabetes. " | ( A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Chou, HS; Goldberg, RB; Merante, D; Rosenstock, J; Triscari, J; Truitt, KE; Wang, AC, 2010) | 2.04 |
| "Rivoglitazone is an efficacious, safe and well-tolerated TZD which improved glycaemic control in Chinese type 2 diabetic patients up to 3 months." | ( A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Asami, T; Chan, JC; Ko, GT; Kong, AP; Lee, KF; Leung, GT; Ohwada, S; Ozaki, R; Saito, H; Wong, CK; Yamasaki, A; Yeung, CY, 2011) | 2.05 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rivoglitazone has been shown, through small clinical studies, to decrease hemoglobin A(1c) (A1C) by 0.11-1.1% when compared with placebo and may provide greater A1C reduction than pioglitazone. " | ( Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Koffarnus, RL; Phillippe, HM; Wargo, KA, 2013) | 3.28 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic model involving chiral inversion explained well the plasma profiles of R-isomer and S-isomer after intravenous and oral administration of (R)-rivoglitazone or (S)-rivoglitazone to rats and monkeys." | ( Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach. Ishizuka, T; Izumi, T; Kothuma, M; Nakamura, K; Takahashi, M; Tsuruta, F, 2013) | 0.85 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral bioavailability was high (>95% in rats and >76." | ( Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys. Abe, K; Iwabuchi, H; Izumi, T; Koda, H; Oguchi, M; Okazaki, O; Takahashi, M; Tsuruta, F; Uchiyama, M, 2011) | 0.62 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment requires frequent dosing and often lacks complete efficacy." | ( Emerging drugs for conjunctivitis. Bielory, L; Origlieri, C, 2009) | 0.35 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | EC50 (µMol) | 0.0430 | 0.0000 | 0.9922 | 10.0000 | AID1362964 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleus | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| nucleoplasm | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| cytosol | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| RNA polymerase II transcription regulator complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| chromatin | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| receptor complex | Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1362965 | Agonist activity at recombinant human GAL4-DBD fused PPARgamma LBD expressed in COS7 cells at 10 uM after 24 hrs by luciferase reporter gene assay relative to rosiglitazone | 2018 | Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18 | Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification. |
| AID1362964 | Agonist activity at recombinant human GAL4-DBD fused PPARgamma LBD expressed in COS7 cells after 24 hrs by luciferase reporter gene assay | 2018 | Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18 | Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.32) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (26.67%) | 5.53% |
| Reviews | 3 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (53.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||